Balyasny Asset Management LLC Arcutis Biotherapeutics, Inc. Transaction History

Balyasny Asset Management LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$7.24 - $12.53 $2.49 Million - $4.3 Million	-343,418 Reduced 43.98%	437,362 $4.07 Million
Q1 2024 May 13, 2024	BUY	$3.25 - $11.77 $2.54 Million - $9.19 Million	780,780 New	780,780 $7.74 Million
Q3 2023 Nov 14, 2023	BUY	$5.31 - $10.98 $202,146 - $417,997	38,069 New	38,069 $202,000
Q1 2023 May 15, 2023	BUY	$10.23 - $17.14 $453,066 - $759,096	44,288 New	44,288 $487,000

196

130M

738K

82K

Ticker ARQT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,187,500
Market Cap $797M
Description
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing A...

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Balyasny Asset Management LLC with notifications on news.